增生性玻璃体视网膜病变的药物治疗

Pharmaceutical treating progression of proliferative vitreoretinopathy

增生性玻璃体视网膜病变(PVR)常由于裂孔源性视网膜脱离、眼穿孔伤或眼内手术造成血-视网膜屏障受损,视网膜色素上皮(RPE)细胞进入玻璃体,继而引起RPE细胞、神经胶质细胞、成纤维细胞等在玻璃体内增生,形成以细胞为主的纤维膜。临床上治疗和预防PVR以手术为主,但效果不佳。近来有许多药物治疗PVR的研究报道,就PVR药物治疗研究进展进行综述。

Proliferative vitreoretinopathy（PVR） often are induced due to rhegmatogenous retinal detachment,ocular injury or intraocular surgery.In the pathogenesis of PVR,damage of blood-retinal barrier,migration of retinal pigment epithelial（RPE） cells into vitreous and the proliferation of RPE cells,glial cells,fibroblasts in vitreous as well as further formation of a cell-based fiber membrane are the main mechanisms.Clinical treating method of PVR is vitrectomy.However,the outcome of therapeutic effect is often not ideal.Recently,many studies on pharmaceutical treatment of PVR have been reported.The recent study progression of pharmaceutical treatment of PVR are overviewed.